Ann: Acrux's fifth generic dossier accepted by FDA for review, page-6

@parfait and @jetrodder, you are both are definitely onto something here that makes me think not so much about expanding the testosterone market via dosage (which is a great life cycle extension play) but more so about is there something unique about the Dapsone space.

7.5% - annual sales USD 206mil but litigation, so the brand is enjoying that position.
5.0% - annual sales USD 30mil no litigation, two existing competitors the brand and one generic.

Why would you bother with spending $ on the 5% unless it is a non litigation pathway into the 7.5% market, which is clearly the one to break into from a $$ perspective.

Just thinking aloud, would love a pharma guys view and wish ACR would be more transparent with us.